Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J. Nutt

Showing results (11-20 of 329) with videos related to

Pageof 33
Sort By:
International Clinical Psychopharmacology|October 9, 2002
The neuropharmacology of serotonin and noradrenaline in depressionDavid J Nutt
The Lancet. Psychiatry|February 14, 2025
Drug development in psychiatry: 50 years of failure and how to resuscitate itDavid J Nutt
Journal of Psychopharmacology (Oxford, England)|July 12, 2011
Substitution therapy for alcoholism: time for a reappraisal?Jonathan Chick, David J Nutt
Neurobiology of Disease|May 21, 2013
CNS drug development in Europe--past progress and future challengesDavid J Nutt, Jim Attridge
Journal of Psychopharmacology (Oxford, England)|May 6, 2005
Gamma hydroxy butyrate abuse and dependencyAlejandro Gonzalez, David J Nutt
Journal of Psychopharmacology (Oxford, England)|September 20, 2011
Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?Ruth Weissenborn, David J Nutt
Journal of Psychopharmacology (Oxford, England)|January 9, 2014
Doing it by numbers: a simple approach to reducing the harms of alcoholDavid J Nutt, Jürgen Rehm
Synapse (New York, N.Y.)|June 20, 2015
Optimising PET approaches to measuring 5-HT release in human brainRobin J Tyacke, David J Nutt
Journal of Psychopharmacology (Oxford, England)|November 28, 2009
Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnoticsDavid J Nutt, S M Stahl
Psychopharmacology|November 30, 2013
Effects of upper respiratory tract illnesses, ibuprofen and caffeine on reaction time and alertnessAndrew P Smith, David J Nutt
Pageof 33

Showing results (11-20 of 329) with videos related to

Sort By:
Pageof 33
International Clinical Psychopharmacology|October 9, 2002
The neuropharmacology of serotonin and noradrenaline in depressionDavid J Nutt
The Lancet. Psychiatry|February 14, 2025
Drug development in psychiatry: 50 years of failure and how to resuscitate itDavid J Nutt
Journal of Psychopharmacology (Oxford, England)|July 12, 2011
Substitution therapy for alcoholism: time for a reappraisal?Jonathan Chick, David J Nutt
Neurobiology of Disease|May 21, 2013
CNS drug development in Europe--past progress and future challengesDavid J Nutt, Jim Attridge
Journal of Psychopharmacology (Oxford, England)|May 6, 2005
Gamma hydroxy butyrate abuse and dependencyAlejandro Gonzalez, David J Nutt
Journal of Psychopharmacology (Oxford, England)|September 20, 2011
Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?Ruth Weissenborn, David J Nutt
Journal of Psychopharmacology (Oxford, England)|January 9, 2014
Doing it by numbers: a simple approach to reducing the harms of alcoholDavid J Nutt, Jürgen Rehm
Synapse (New York, N.Y.)|June 20, 2015
Optimising PET approaches to measuring 5-HT release in human brainRobin J Tyacke, David J Nutt
Journal of Psychopharmacology (Oxford, England)|November 28, 2009
Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnoticsDavid J Nutt, S M Stahl
Psychopharmacology|November 30, 2013
Effects of upper respiratory tract illnesses, ibuprofen and caffeine on reaction time and alertnessAndrew P Smith, David J Nutt
Pageof 33